Pacira BioSciences/$PCRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pacira BioSciences
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Ticker
$PCRX
Sector
Primary listing
Employees
789
Headquarters
Website
PCRX Metrics
BasicAdvanced
$1.1B
-
-$2.27
0.49
-
Price and volume
Market cap
$1.1B
Beta
0.49
52-week high
$27.64
52-week low
$11.16
Average daily volume
597K
Financial strength
Current ratio
2.415
Quick ratio
1.902
Long term debt to equity
53.218
Total debt to equity
79.703
Interest coverage (TTM)
5.17%
Profitability
EBITDA (TTM)
171.812
Gross margin (TTM)
65.69%
Net profit margin (TTM)
-14.76%
Operating margin (TTM)
13.13%
Effective tax rate (TTM)
-52.45%
Revenue per employee (TTM)
$890,000
Management effectiveness
Return on assets (TTM)
3.64%
Return on equity (TTM)
-12.27%
Valuation
Price to revenue (TTM)
1.508
Price to book
1.33
Price to tangible book (TTM)
3.1
Price to free cash flow (TTM)
6.647
Free cash flow yield (TTM)
15.04%
Free cash flow per share (TTM)
3.451
Growth
Revenue change (TTM)
3.08%
Earnings per share change (TTM)
-260.16%
3-year revenue growth (CAGR)
6.58%
10-year revenue growth (CAGR)
12.35%
3-year earnings per share growth (CAGR)
39.33%
10-year earnings per share growth (CAGR)
54.50%
What the Analysts think about PCRX
Analyst ratings (Buy, Hold, Sell) for Pacira BioSciences stock.
Bulls say / Bears say
Pacira BioSciences announced a $300 million share repurchase program, signaling confidence in its financial health and commitment to enhancing shareholder value. (nasdaq.com)
The company reported better-than-expected preliminary Q4 2024 sales figures, with Exparel's net product sales reaching $147.7 million, a 3% increase from the previous year. (nasdaq.com)
Pacira unveiled promising three-year clinical data for its investigational gene therapy, PCRX-201, showing sustained improvements in knee osteoarthritis patients, which could lead to future product approvals and revenue streams. (stocktitan.net)
In Q3 2024, Pacira reported a $163.2 million impairment charge, significantly impacting its financial results and raising concerns about asset valuation. (stocktitan.net)
The company faced a legal setback when a U.S. court deemed its '495 patent for Exparel invalid, potentially opening the market to generic competition and affecting future revenues. (zacks.com)
Insider trading activity over the past six months shows that company executives have sold shares, which might indicate a lack of confidence in the stock's short-term performance. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
PCRX Financial Performance
Revenues and expenses
PCRX Earnings Performance
Company profitability
PCRX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pacira BioSciences stock?
Pacira BioSciences (PCRX) has a market cap of $1.1B as of August 05, 2025.
What is the P/E ratio for Pacira BioSciences stock?
The price to earnings (P/E) ratio for Pacira BioSciences (PCRX) stock is 0 as of August 05, 2025.
Does Pacira BioSciences stock pay dividends?
No, Pacira BioSciences (PCRX) stock does not pay dividends to its shareholders as of August 05, 2025.
When is the next Pacira BioSciences dividend payment date?
Pacira BioSciences (PCRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Pacira BioSciences?
Pacira BioSciences (PCRX) has a beta rating of 0.49. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.